In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this live activity for a maximum of 13.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.


Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by December 27,2023 Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Request For Credit Survey

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Printable List of CME-Designated Sessions

Statement of Educational Need, Target Audience, and Learning Objectives

In the United States, the number of women diagnosed with EC by 2030 will increase to 122,000 cases per year if current trends continue. The core goals for clinicians and oncologists in combating endometrial cancer are prevention, screening, classification, treatment and importantly understanding and reducing the disparities in EC treatment. This conference will focus heavily on prevention, treatment, and disparities in endometrial cancer.

Although universal screening in patients with EC who are <70 years of age is cost-effective there are logistical barriers to such screening, including insufficient tissue for testing and patients declining tissue or germline testing. Estimating the risk of disease recurrence as well has historically been challenging for EC given variability in surgical practice and the lack of reproducible pathological classification. Consequently, treatment of newly diagnosed EC is variable between regions and across treatment centers. Current promising research includes continuing efforts towards improved molecular stratification of endometrial tumors. Improved classification can better inform treatment. Enhanced genetic profiling methods are underway to aid oncologists more rapidly by linking genetic signatures to diagnosis and prognosis and bringing patients into the appropriate clinical trials.

Black women have significantly higher mortality rates compared with white women, even when controlling for known high-risk factors such as stage and non-endometrioid histology. Some reasons for this disparity include quality of care given to women of color, implicit racial bias and systemic racism and the non-inclusion of underrepresented minorities in clinical trials and molecular studies. Therefore, there is a critical need for systematic investigation and research funding so these disparities can be scrutinized, addressed, and successfully overcome.

Next-generation sequencing is being used to analyze circulating and shed tumor cells to identify new biomarkers. These new biomarkers are then studied to determine usefulness in diagnosis, prognostication, and prediction of response to therapy. Novel universal gene mutations that could be acting as cancer drivers are being discovered, which can then be evaluated as drug targets. Furthermore, using genomic and proteomic analysis to detect correlation between gene profiles and outcomes can inform outcomes and risk.

Immunotherapy and targeted therapies are also being researched for use in women with endometrial cancer. Understanding ways of utilizing the body’s immune system to fight cancer is one of the most promising areas of cancer research.

To comprehensively manage EC, dedicated efforts to delineate host factors more precisely, such as microbiome composition and the effect of body mass index (BMI), are imperative, as is a deeper understanding of the molecular and immunological drivers of response and resistance to emerging therapies, which is critically important for the optimal design of next-generation studies.

After participating in this CME activity, physicians should be able to:

  1. Identify and integrate novel strategies for preventing endometrial tumors.
  2. Address and reduce the number of underrepresented minority populations who disproportionately suffer and die from endometrial malignancy.
  3. Analyze novel genetic mutations that could be acting as cancer drivers.
  4. Integrate novel immunotherapies, targeted therapies, and combination therapies for personalized cancer treatment.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.

Planner and Speaker Financial Index

Acknowledgment of Financial or Other Support

The AACR gratefully acknowledges the following commercial supporters for their Professional Educational Grants:

  • Merck
  • GSK

Questions about CME?

Please read our frequently asked questions. If you still have questions, contact the Office of CME at (215) 440-9300 or [email protected].